Rosacea in Patients with Ulcerative Colitis and Crohn's Disease: A Population-based Case-control Study

Inflammatory Bowel Diseases

Volumn 22, Issue 3, 2016, Pages 680-687

  Spoendlin, Julia ^a,b   Karatas, Gulistan ^a   Furlano, Raoul I ^c   Jick, Susan S ^d   Meier, Christoph R ^a,b,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

clinical practice research datalink; Crohn's disease; epidemiology; rosacea; Ulcerative colitis

Indexed keywords

ADULT; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; CROHN DISEASE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR; ROSACEA; SEVERITY OF ILLNESS INDEX; SWITZERLAND; ULCERATIVE COLITIS;

ADULT; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; ROSACEA; SEVERITY OF ILLNESS INDEX; SWITZERLAND;

EID: 84959361686     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000644     Document Type: Article

References (39)

1. Corridoni D, Arseneau KO, Cominelli F. Inflammatory bowel disease. Immunol Lett. 2014;161:231-235.
2. Ford AC, Moayyedi P, Hanauer SB, et al. Ulcerative colitis. Br Med J. 2013;346:f432.
3. Lunney PC, Leong RWL. Review article: ulcerative colitis, smoking and nicotine therapy. Aliment Pharmacol Ther. 2012;36:997-1008.
4. Tavano F, Palmieri O, di Mola FF, et al. Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases. Dig Liver Dis. 2013;45:1-8.
5. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:2-11.
6. de Fontgalland D, Brookes SJ, Gibbins I, et al. The neurochemical changes in the innervation of human colonic mesenteric and submucosal blood vessels in ulcerative colitis and Crohn's disease. Neurogastroenterol Motil. 2014;26:731-744.
7. Thrash B, Patel M, Shah KR, et al. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68:211.e1-33.
8. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341.
9. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206.
10. Powell FC. Rosacea. N Engl J Med. 2005;352:793-803.
11. van Zuuren EJ, Kramer SF, Carter BR, et al. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol. 2011;165:760-781.
12. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J AmAcadDermatol. 2013;69:S15-S26.
13. Dessoukey MW, Omar MF, Dayem HA. Pyoderma faciale: manifestation of inflammatory bowel disease. Int J Dermatol. 1996;35:724-726.
14. Sigl I, Bauerdorf R. Granulomatous rosacea associated with ulcerative colitis: 2 case reports [in German]. Z Hautkr. 1989;64:499-502.
15. Walton S, Sheth M, Wyatt EH. Rosacea and ulcerative colitis: a possible association. J Clin Gastroenterol. 1990;12:513-515.
16. Romiti R, Jansen T, Heldwein W, et al. Rosacea fulminans in a patient with Crohn's disease: a case report and review of the literature. Acta Derm Venereol. 2000;80:127-129.
17. Jansen T, Plewig G. Fulminating rosacea conglobata (rosacea fulminans) and ulcerative colitis. Br J Dermatol. 1997;137:830-831.
18. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60:e128-e136.
19. Walley T, Mantgani A. The UK general practice research database. Lancet. 1997;350:1097-1099.
20. Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf. 2004;27:871-881.
21. Spoendlin J, Voegel JJ, Jick SS, et al. A study on the epidemiology of rosacea in the U.K. Br J Dermatol. 2012;167:598-605.
22. Spoendlin J, Voegel JJ, Jick SS, et al. Antihypertensive drugs and the risk of incident rosacea. Br J Dermatol. 2014;171:1-7.
23. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657-663.
24. Osterman MT, Yang YX, Brensinger C, et al. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:875-880.
25. Lewis JD, Brensinger C, Bilker WB, et al. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2002;11:211-218.
26. National Institute for Health and Care Excellence. Crohn's Disease-Managment in Adult, Children and Young People (CG152). England, United Kingdom: National Institute for Health and Care Excellence; 2012.
27. National Institute for Health and Care Excellence. Ulcerative Colitis-Management in Adults, Children and Young People (CG166). England, United Kingdom: National Institute for Health and Care Excellence; 2013.
28. National Institute for Health and Care Excellence. Infliximab for Acute Exacerbations of Ulcerative Colitis (Technol. Apprais. Guid. 163). England, United Kingdom: National Institute for Health and Care Excellence; 2009.
29. Hameed AF. Steroid dermatitis resembling rosacea: a clinical evaluation of 75 patients. ISRN Dermatol. 2013;2013:491376.
30. Passarini B, Infusino SD, Barbieri E, et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by antitumor-necrosis-factor antibody therapy. Dermatology. 2007;215:295-300.
31. VanderWeele TJ, Hernán MA, Robins JM. Causal directed acyclic graphs and the direction of unmeasured confounding bias. Epidemiology. 2008; 19:720-728.
32. Brant SR. Promises, delivery, and challenges of inflammatory bowel disease risk gene discovery. Clin Gastroenterol Hepatol. 2013;11:22-26.
33. Jäger S, Stange EF, Wehkamp J. Inflammatory bowel disease: an impaired barrier disease. Langenbecks Arch Surg. 2013;398:1-12.
34. Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol. 2013;29:357-362.
35. Ueno A, Jijon H, Traves S, et al. Opposing effects of smoking in ulcerative colitis and Crohn's disease may be explained by differential effects on dendritic cells. Inflamm Bowel Dis. 2014;0:1-11.
36. Lakatos PL, Vegh Z, Lovasz BD, et al. Is current smoking still an important environmental factor in inflammatory bowel diseases Results from a population-based incident cohort. Inflamm Bowel Dis. 2013;19:1010-1017.
37. Abram K, Silm H, Maaroos HI, et al. Subjective disease perception and symptoms of depression in relation to healthcare-seeking behaviour in patients with rosacea. Acta Derm Venereol. 2009;89:488-491.
38. Elewski BE, Draelos Z, Dreno B, et al. Rosacea-global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25:188-200.
39. Kosmidou M, Gaitanis G, Nomikos K, et al. Severe rosacea in a patient on infliximab for ulcerative colitis: pathophysiological considerations. Acta Derm Venereol. 2009;89:522-523.